CN103751700A - Danshilitong tablet preparation method and application of Danshilitong tablets in preparation of lymphoid neoplasm cell P388D1 proliferation inhibition drugs - Google Patents
Danshilitong tablet preparation method and application of Danshilitong tablets in preparation of lymphoid neoplasm cell P388D1 proliferation inhibition drugs Download PDFInfo
- Publication number
- CN103751700A CN103751700A CN201310672108.0A CN201310672108A CN103751700A CN 103751700 A CN103751700 A CN 103751700A CN 201310672108 A CN201310672108 A CN 201310672108A CN 103751700 A CN103751700 A CN 103751700A
- Authority
- CN
- China
- Prior art keywords
- preparation
- extraction
- danshilitong
- cholelithiasis treating
- danshitongli tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a preparation method and an application of Danshilitong tablets, wherein the Danshilitong tablets are prepared by adopting 225 g of dichondra repens forst, 225 g of artemisiacapillaris thunb, 90 g of curcuma aromatica salisb, 150 g of tangerine peel, 45 g of scutellaria baicalensis georgi, 35 g of boswellia carteri, 80 g of mirabilite, 35 g of alunite, 45 g of rheum, 45 g of common burreed tuber, 45 g of cape jasmine, 25 g of licorice root, and 35 g of myrrh as bulk drugs. According to the prevent invention, ultra-fine crushing, supercritical fluid extraction, microwave extraction and macroporous resin absorption are performed to prepare the Danshilitong tablets, such that the hesperidin content is substantially increased. The present invention further provides the application of the Danshilitong tablets in preparation of mouse lymphoid neoplasm cell P388D1 proliferation inhibition drugs.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of preparation method of cholelithiasis treating Danshitongli tablet and suppress the application in mouse lymph sample oncocyte P388D1 cell proliferation medicine in preparation.
Background technology
DanShiTongLi capsules standard No. WS-10324(ZD-0324)-2002, be recorded in national standard for traditional Chinese medicines compilation internal medicine liver and gall fascicle.By Herba Lysimachiae 225g, Herba Artemisiae Scopariae 225g, Radix Curcumae 90g, Pericarpium Citri Reticulatae 150g, Radix Scutellariae 45g, Olibanum 35g, Natrii Sulfas 80g, Alumen 35g, Radix Et Rhizoma Rhei 45g, Rhizoma Sparganii 45g, Fructus Gardeniae 45g, Radix Glycyrrhizae 25g, Myrrha 35g, as crude drug, made, there is clearing heat secreting bile, blood stasis dispelling calculus removing effect.For the acute and chronic cholecystitis due to dampness-heat in the liver and gallbladder, cholelithiasis etc.
In prior art, not yet there is DanShiTongLi capsules adopting micronizing, CO aspect extraction preparation
2the report that supercritical extraction, microwave technology and macroporous adsorption resin technology extract, and Chinese medicine is directly beaten the method that powder is got, decocting boils, technique is coarse, backward, and impurity is many, causes patient's consumption excessive, is inconvenient to take, and has had a strong impact on this product and has applied clinically.
Summary of the invention
In order to solve above-mentioned technical problem, the invention provides a kind of preparation method of cholelithiasis treating Danshitongli tablet.
Another object of the present invention is to provide a kind of cholelithiasis treating Danshitongli tablet to suppress the application in mouse lymph sample oncocyte P388D1 cell proliferation medicine in preparation.
The object of the invention is to realize by following scheme:
A kind of preparation method of cholelithiasis treating Danshitongli tablet, by Herba Lysimachiae 225g, Herba Artemisiae Scopariae 225g, Radix Curcumae 90g, Pericarpium Citri Reticulatae 150g, Radix Scutellariae 45g, Olibanum 35g, Natrii Sulfas 80g, Alumen 35g, Radix Et Rhizoma Rhei 45g, Rhizoma Sparganii 45g, Fructus Gardeniae 45g, Radix Glycyrrhizae 25g, Myrrha 35g, as crude drug, made, described preparation method is comprised of the following step: Natrii Sulfas, Alumen micronizing become the fine powder of particle size range 5-45 μ m standby, get Olibanum, Myrrha, be ground into fine powder, join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 ℃, CO
2flow l-3ml/g crude drug min, extraction time 180-220min, obtains supercritical extract, standby, Olibanum after extraction, Myrrha residue and other nine tastes medical materials, pulverize, 70% ethanol that adds 3.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 600-800W, extract 2 times, each 5-10 minute, combining extraction liquid, concentrated, be added on Diaion HP-10 macroporous adsorptive resins, 70% ethanol elution, collect 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, by the Natrii Sulfas after micronizing, Alumen, supercritical extract, microwave extraction thing mixes and adds starch, 70% ethanol granule processed, dry, tabletting, make 500, every heavy 0.3g.
In the preparation method of above-mentioned cholelithiasis treating Danshitongli tablet, described CO
2in supercritical extraction, to account for the percent by volume of total extractant be 5% to entrainer.
In the preparation method of above-mentioned cholelithiasis treating Danshitongli tablet, described CO
2in supercritical extraction, extracting pressure is 25MPa.
In the preparation method of above-mentioned cholelithiasis treating Danshitongli tablet, described CO
2in supercritical extraction, extraction temperature is 60 ℃.
In the preparation method of above-mentioned cholelithiasis treating Danshitongli tablet, described CO
2cO in supercritical extraction
2flow 2ml/g crude drug min.
In the preparation method of above-mentioned cholelithiasis treating Danshitongli tablet, described CO
2in supercritical extraction, extraction time is 200min.
In the preparation method of above-mentioned cholelithiasis treating Danshitongli tablet, described microwave extracting power is 700W.
In the preparation method of above-mentioned cholelithiasis treating Danshitongli tablet, the each extraction time of described microwave extracting is 8 minutes.
Above-mentioned cholelithiasis treating Danshitongli tablet suppresses the application in mouse lymph sample oncocyte P388D1 cell proliferation medicine in preparation.
In prior art, DanShiTongLi capsules is oral, one time 5,3 times on the one.DanShiTongLi capsules dosage is large.The every heavy 0.3g of cholelithiasis treating Danshitongli tablet that adopts the inventive method to be prepared into only needs 2 at every turn, within 1st, takes 3 times.Greatly reduced dose having under the condition of more active component.This conclusion can be by following evidence.
The comparison of content of hesperidin in cholelithiasis treating Danshitongli tablet prepared by test one, distinct methods
L, instrument and reagent cholelithiasis treating Danshitongli tablet of the present invention: press embodiment 1 method preparation, use 1080g crude drug, make 500 through extracting, every heavy 0.3g.Former DanShiTongLi capsules, according to WS-10324(ZD-0324)-2002 standard method preparations, in contrast.Agilent1200 high performance liquid chromatograph; AE240 electronic analytical balance; Hesperidin reference substance (Nat'l Pharmaceutical & Biological Products Control Institute).
2, method
According to high performance liquid chromatography (appendix V D of Chinese Pharmacopoeia version in 2010), measure.
Strong to close silica gel be filler by octadecylsilane for chromatographic condition and system suitability; Methanol-water (40: 60) is mobile phase; Detection wavelength is 284nm; Number of theoretical plate calculates and should be not less than 3000 by Hesperidin peak.
It is appropriate that the preparation precision of reference substance solution takes Hesperidin reference substance, adds methanol and make every 1ml containing the solution of 38 μ g, obtains.
Cholelithiasis treating Danshitongli tablet of the present invention is got in the preparation of product need testing solution of the present invention, and porphyrize is got 0.06g,, accurately weighed, put in tool plug conical flask, precision adds Diluted Alcohol 25ml, weighed weight, close plug, supersound process (power 250w, frequency 30kHz) 40 minutes, lets cool, weighed weight, and with Diluted Alcohol, supply the weight of less loss, shake up, filter, get subsequent filtrate, obtain.
The DanShiTongLi capsules of this contrast is got in the preparation of reference substance need testing solution, mixes porphyrize, get 0.15g, accurately weighed, put in tool plug conical flask, precision adds Diluted Alcohol 25ml, weighed weight, close plug, supersound process (power 250w, frequency 30kHz) 40 minutes, lets cool, weighed weight, and with Diluted Alcohol, supply the weight of less loss, shake up, filter, get subsequent filtrate, obtain.
Algoscopy is accurate reference substance solution and each 10 μ l of need testing solution of drawing respectively, and injection liquid chromatography, measures, and obtains.
3, result
Result shows, in cholelithiasis treating Danshitongli tablet of the present invention, the content of Hesperidin is 6-10mg/ sheet; And the content of Hesperidin is 1.45mg/ grain in former DanShiTongLi capsules, doubly, in the situation that dose reduces, content of hesperidin improves a lot the 4-6 that every content of hesperidin is equivalent to original capsule content.
Above-mentioned research shows, the cholelithiasis treating Danshitongli tablet that adopts preparation method of the present invention to prepare, active constituent content is far away higher than WS-10324(ZD-0324) DanShiTongLi capsules prepared of the method recorded of-2002 standards.
The specific embodiment
Below in conjunction with specific embodiment, the present invention is further described, so that those skilled in the art more understands the present invention, but this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following example, all technology realizing based on foregoing of the present invention all belong to scope of the present invention.
Embodiment 1
Get Herba Lysimachiae 225g, Herba Artemisiae Scopariae 225g, Radix Curcumae 90g, Pericarpium Citri Reticulatae 150g, Radix Scutellariae 45g, Olibanum 35g, Natrii Sulfas 80g, Alumen 35g, Radix Et Rhizoma Rhei 45g, Rhizoma Sparganii 45g, Fructus Gardeniae 45g, Radix Glycyrrhizae 25g, Myrrha 35g: become the fine powder of particle size range 5-45 μ m standby Natrii Sulfas, Alumen micronizing, get Olibanum, Myrrha, be ground into fine powder, join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 25MPa, 40 ℃ of temperature, CO
2flow 2ml/g crude drug min, extraction time 200min, obtains supercritical extract, standby, Olibanum after extraction, Myrrha residue and other nine tastes medical materials, pulverize, 70% ethanol that adds 3.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 700W, extract 2 times, each 8 minutes, combining extraction liquid, concentrated, be added on Diaion HP-10 macroporous adsorptive resins, 70% ethanol elution, collect 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, by the Natrii Sulfas after micronizing, Alumen, supercritical extract, microwave extraction thing mixes and adds starch, 70% ethanol granule processed, dry, tabletting, make 500, every heavy 0.3g.
After testing, in finished product, the content of Hesperidin is 9.86mg/ sheet.
Embodiment 2
Get Herba Lysimachiae 225g, Herba Artemisiae Scopariae 225g, Radix Curcumae 90g, Pericarpium Citri Reticulatae 150g, Radix Scutellariae 45g, Olibanum 35g, Natrii Sulfas 80g, Alumen 35g, Radix Et Rhizoma Rhei 45g, Rhizoma Sparganii 45g, Fructus Gardeniae 45g, Radix Glycyrrhizae 25g, Myrrha 35g: become the fine powder of particle size range 5-45 μ m standby Natrii Sulfas, Alumen micronizing, get Olibanum, Myrrha, be ground into fine powder, join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4%, extracting pressure 30MPa, temperature 50 C, CO
2flow 3ml/g crude drug min, extraction time 180min, obtains supercritical extract, standby, Olibanum after extraction, Myrrha residue and other nine tastes medical materials, pulverize, 70% ethanol that adds 3.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 600W, extract 2 times, each 8 minutes, combining extraction liquid, concentrated, be added on Diaion HP-10 macroporous adsorptive resins, 70% ethanol elution, collect 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, by the Natrii Sulfas after micronizing, Alumen, supercritical extract, microwave extraction thing mixes and adds starch, 70% ethanol granule processed, dry, tabletting, make 500, every heavy 0.3g.
After testing, in finished product, the content of Hesperidin is 6.42mg/ sheet.
Embodiment 3
Get Herba Lysimachiae 225g, Herba Artemisiae Scopariae 225g, Radix Curcumae 90g, Pericarpium Citri Reticulatae 150g, Radix Scutellariae 45g, Olibanum 35g, Natrii Sulfas 80g, Alumen 35g, Radix Et Rhizoma Rhei 45g, Rhizoma Sparganii 45g, Fructus Gardeniae 45g, Radix Glycyrrhizae 25g, Myrrha 35g: become the fine powder of particle size range 5-45 μ m standby Natrii Sulfas, Alumen micronizing, get Olibanum, Myrrha, be ground into fine powder, join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 6%, extracting pressure 15MPa, 30 ℃ of temperature, CO
2flow 1ml/g crude drug min, extraction time 220min, obtains supercritical extract, standby, Olibanum after extraction, Myrrha residue and other nine tastes medical materials, pulverize, 70% ethanol that adds 3.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 800W, extract 2 times, each 10 minutes, combining extraction liquid, concentrated, be added on Diaion HP-10 macroporous adsorptive resins, 70% ethanol elution, collect 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, by the Natrii Sulfas after micronizing, Alumen, supercritical extract, microwave extraction thing mixes and adds starch, 70% ethanol granule processed, dry, tabletting, make 500, every heavy 0.3g.
After testing, in finished product, the content of Hesperidin is 8.26mg/ sheet.
Embodiment 4: cholelithiasis treating Danshitongli tablet suppresses the experimentation data of mouse lymph sample oncocyte P388D1 cell proliferation
1. experiment material
1.1 experiment cell strains
Mouse lymph sample oncocyte P388D1 cell, Shandong University's laboratory cell bank, DMEM+10%FBS cellar culture.
1.2 Experimental agents
Drugs: cholelithiasis treating Danshitongli tablet of the present invention: press embodiment 1 method preparation.
Medicinal liquid liquid storage: take 100mg cholelithiasis treating Danshitongli tablet, be dissolved in 5ml dehydrated alcohol, 0.2 μ m filter filters, 500 μ ldoff pipe subpackages ,-20 ℃ of storages, 0.2 μ m filter filters dehydrated alcohol in order to the use of matched group simultaneously.
1.3 experiment reagent
DMEM (Cat.No.12100-061Lot.No.758137 of GIBCO company); Hyclone (Lot.No.100419 of Tian Hang bio tech ltd, Zhejiang); NaHC03 (Cat.No.11810-033Lot.No.1088387 of Shanghai Jiu Yi chemical reagent company limited); Trypsin(AMRESCO company); EDTA(AMRESCO company); Penicillin G Sodium Salt(AMRESCO company 1); Streptomycin Sulfate (AMRESCO); Dehydrated alcohol (Zibo Ya Dulan Trade Co., Ltd.); MTT (Biosharp lot number: 0793): the autogamy of PBS(laboratory);
1.4 experiment equipment
Lycra inverted microscope (German Leica model: DMIL); Visible-ultraviolet light microwell plate detector (U.S. MD company model: SPECTRAMAX190); C0
2incubator (FORMA model: 3111); (safe and sound company of Su Jing group manufactures model to super-clean bench: SW-CJ-ZFD); Pure water instrument (U.S. Sprlng company model: S/N020579); Accurate pipettor (French Gilson Inc model: P2); Electronic balance (German Sai Duolisi company limited model: BT323S); Full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020); Table electrothermal air dry oven (Shanghai accurate experimental facilities company model: DHG9123A); Refrigerator (Siemens Company's model: KG18V21TI); Liquid nitrogen container (CBS model: 2001); Low speed centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000); 0.2 μ m filter (MILLIPORE model: SLGP033RB); 1cm culture dish (NEST company), 96 well culture plates (NEST company); Cell counting count board; Centrifuge tube, pipet, Tips are some.
2. experimental technique
1) P388D1 cell uses DMEM+10%FBS in 37 ℃, 5%C0
2carry out cellar culture (10cm culture dish), when Growth of Cells is during to logarithmic (log) phase, collecting cell, discards culture fluid, PBS fine laundering 3 times, add 3ml0.25% trypsin-0.04%EDTA, after 37 ℃ of digestion 2min, add wherein 5ml complete medium neutralization reaction, after piping and druming cell, proceeded in centrifuge tube, the centrifugal 5min of 1000rpm, adjusts concentration of cell suspension 3 * 10
4individual/ml.
2) cell kind is entered in 96 well culture plates, every hole adds cell suspension 180 μ l, culture plate put into cell culture incubator (37 ℃, 5%C0
2) cellar culture.
3) according to Growth of Cells situation, generally grow to 50%-70%, add cholelithiasis treating Danshitongli tablet solution, continue to cultivate 24h.
4) after 24h, add 20 μ l MTT solution (5mg/ml, i.e. 0.5%MTT), continue to cultivate 4h.
5) after 4h, buckle method is removed supernatant, with absorbent paper, pats dry gently, and low-speed oscillation 10min on shaking table, as entered 200 μ l dimethyl sulfoxide, is put in every hole, and crystal is fully dissolved.At enzyme-linked immunosorbent assay instrument 490nm place, measure the light absorption value in each hole.
6) background (do not add cell, only add culture fluid) is set simultaneously, control wells (the medicine dissolution medium of cell, same concentrations, culture fluid, MTT, dimethyl sulfoxide), sets 6 multiple holes for every group.
7) result represents the suppression ratio of cell with medicine: cell increment suppression ratio (%)=(control wells OD value-dosing holes OD value), control wells OD value * 100%.Experiment repeats 3 times.
3. statistical disposition
Adopt correlation analysis and Student t check in Microsoft Excel2007 software, data represent with mean ± S.D..
4. experimental result
Statistical result showed after mtt assay experiment, with matched group comparison, when dosage reaches 5mg/ml, to P388D1 cell inhibitory effect variant (P<0.05), dosage this difference when 10mg/ml has significance (P<0.01), has utmost point significant difference (P<0.001) when dosage reaches 15-20mg/ml.
Table 1 cholelithiasis treating Danshitongli tablet is on P388D1 cell inhibitory effect impact research (X ± SD)
| Group | Drug level (mg/ml) | Suppression ratio (%) |
| Matched group | 0 | 0 |
| 1 | 5 | 10.45±7.65 |
| 2 | 10 | 18.44±10.67* |
| 3 | 15 | 28.62±14.01** |
| 4 | 20 | 39..06±15.69** |
Note: with matched group comparison, * P<O.01; * P<0.001.
5. experiment conclusion
Cholelithiasis treating Danshitongli tablet can suppress P388D1 cell proliferation, reduces the Growth of Cells number of P388D1 cell, and this effect is dose dependent.
Claims (9)
1. the preparation method of a cholelithiasis treating Danshitongli tablet, by Herba Lysimachiae 225g, Herba Artemisiae Scopariae 225g, Radix Curcumae 90g, Pericarpium Citri Reticulatae 150g, Radix Scutellariae 45g, Olibanum 35g, Natrii Sulfas 80g, Alumen 35g, Radix Et Rhizoma Rhei 45g, Rhizoma Sparganii 45g, Fructus Gardeniae 45g, Radix Glycyrrhizae 25g, Myrrha 35g, as crude drug, made, it is characterized in that, described preparation method is comprised of the following step: Natrii Sulfas, Alumen micronizing become the fine powder of particle size range 5-45 μ m standby, get Olibanum, Myrrha, be ground into fine powder, join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 ℃, CO
2flow l-3ml/g crude drug min, extraction time 180-220min, obtains supercritical extract, standby, Olibanum after extraction, Myrrha residue and other nine tastes medical materials, pulverize, 70% ethanol that adds 3.6L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 600-800W, extract 2 times, each 5-10 minute, combining extraction liquid, concentrated, be added on Diaion HP-10 macroporous adsorptive resins, 70% ethanol elution, collect 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, by the Natrii Sulfas after micronizing, Alumen, supercritical extract, microwave extraction thing mixes and adds starch, 70% ethanol granule processed, dry, tabletting, make 500, every heavy 0.3g.
2. according to the preparation method of the cholelithiasis treating Danshitongli tablet described in claim l, it is characterized in that described CO
2in supercritical extraction, to account for the percent by volume of total extractant be 5% to entrainer.
3. according to the preparation method of the cholelithiasis treating Danshitongli tablet described in claim l, it is characterized in that described CO
2in supercritical extraction, extracting pressure is 25MPa.
4. according to the preparation method of the cholelithiasis treating Danshitongli tablet described in claim l, it is characterized in that described CO
2in supercritical extraction, extraction temperature is 60 ℃.
5. according to the preparation method of the cholelithiasis treating Danshitongli tablet described in claim l, it is characterized in that described CO
2cO in supercritical extraction
2flow 2ml/g crude drug min.
6. according to the preparation method of the cholelithiasis treating Danshitongli tablet described in claim l, it is characterized in that described CO
2in supercritical extraction, extraction time is 200min.
7. according to the preparation method of the cholelithiasis treating Danshitongli tablet described in claim l, it is characterized in that, described microwave extracting power is 700W.
8. according to the preparation method of the cholelithiasis treating Danshitongli tablet described in claim l, it is characterized in that, the each extraction time of described microwave extracting is 8 minutes.
9. the cholelithiasis treating Danshitongli tablet described in claim l suppresses the application in mouse lymph sample oncocyte P388D1 cell proliferation medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310672108.0A CN103751700A (en) | 2013-12-10 | 2013-12-10 | Danshilitong tablet preparation method and application of Danshilitong tablets in preparation of lymphoid neoplasm cell P388D1 proliferation inhibition drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310672108.0A CN103751700A (en) | 2013-12-10 | 2013-12-10 | Danshilitong tablet preparation method and application of Danshilitong tablets in preparation of lymphoid neoplasm cell P388D1 proliferation inhibition drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103751700A true CN103751700A (en) | 2014-04-30 |
Family
ID=50519127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310672108.0A Pending CN103751700A (en) | 2013-12-10 | 2013-12-10 | Danshilitong tablet preparation method and application of Danshilitong tablets in preparation of lymphoid neoplasm cell P388D1 proliferation inhibition drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103751700A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105030868A (en) * | 2015-09-08 | 2015-11-11 | 南京正亮医药科技有限公司 | Extraction method for plant composition containing silybum marianum and application of plant composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988723A (en) * | 2012-10-08 | 2013-03-27 | 李正梅 | Preparation method and application of yin tonifying and calming tablet |
-
2013
- 2013-12-10 CN CN201310672108.0A patent/CN103751700A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988723A (en) * | 2012-10-08 | 2013-03-27 | 李正梅 | Preparation method and application of yin tonifying and calming tablet |
Non-Patent Citations (1)
| Title |
|---|
| 国家药品监督管理局: "《国家药品标准（试行）颁布件》", 31 December 2002, article "胆石通利胶囊" * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105030868A (en) * | 2015-09-08 | 2015-11-11 | 南京正亮医药科技有限公司 | Extraction method for plant composition containing silybum marianum and application of plant composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103655843A (en) | Yikangbuyuan tablet, and preparation method and application thereof | |
| CN103656493B (en) | A kind of preparation method of blood stasis dispelling stomach reinforcing sheet and application | |
| CN102988550B (en) | Preparation method and application of qinlian tablet | |
| CN103800818A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting myeloma cell FO from cell proliferation | |
| CN103800816A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting stomach cancer cell MFC from cell proliferation | |
| CN102988611B (en) | Preparation method and application of antihypertension tablet | |
| CN103784872B (en) | A kind of preparation method of cholelithiasis treating Danshitongli tablet and the application in preparation suppression Ascitic Tumor Cells SAC-II C3 cell proliferation thereof | |
| CN103751700A (en) | Danshilitong tablet preparation method and application of Danshilitong tablets in preparation of lymphoid neoplasm cell P388D1 proliferation inhibition drugs | |
| CN103751698B (en) | The preparation method of a kind of cholelithiasis treating Danshitongli tablet and the application in preparation suppression prostate gland cancer cell RM-1 cell proliferation thereof | |
| CN103768514A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting myeloma cell SP2/0 from cell proliferation | |
| CN103768517A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting mouse lung cancer cell LLC from cell proliferation | |
| CN103768516A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting stomach cancer cell MFC from cell proliferation | |
| CN103751424A (en) | Preparation method of cold tablet containing Artemisia carvifolia and holly root, and application of cold tablet in teratoma cell F9 cell proliferation inhibition medicines. | |
| CN103690647A (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse leukaemia cell L6565 proliferation | |
| CN103800498A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting mouse prostate cancer cell RM-1 from cell proliferation | |
| CN103893411A (en) | Preparation method and application of green plum cold tablets | |
| CN103751701B (en) | A kind of preparation method of cholelithiasis treating Danshitongli tablet and the application in preparation suppression lymphoma cell YAC-1 cell proliferation thereof | |
| CN103768513B (en) | A kind of preparation method of cholelithiasis treating Danshitongli tablet and the application in preparation inhibition teratocarcinoma cell P19 cell proliferation medicine thereof | |
| CN103751699A (en) | Danshilitong tablet preparation method and application of Danshilitong tablets in preparation of breast tumor cell C127 proliferation inhibition drugs | |
| CN103768508A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting leukaemia cell P815 from cell proliferation | |
| CN103768509A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting Leydig's cell tumor cell MLTC-1 from cell proliferation | |
| CN103768515A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting leukaemia cell L1210 from cell proliferation | |
| CN103768512A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting lymphomata cell EL4.IL-2 from cell proliferation | |
| CN103800819A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting lung cancer cell Hepa1-6 from cell proliferation | |
| CN103768511A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting anus sarcoma cell S-180 from cell proliferation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140430 |
|
| RJ01 | Rejection of invention patent application after publication |